Table 3.

Pharmacokinetics of Flurbiprofen. Data presented as mean ±standard deviation.

	Glomerulonephritis (n=12)	Non-glomerular CKD (n=6)	ESRD (n=8)20	Healthy Controls (n=12) 9	Overall P Value b
Cmax, µg/mL	3.1±1.3c,d	6.6±1.5a,e,f	2.3±0.8a,g	9.4 ± 2.5	<0.0001
Tmax, h	4.8±2.1h,i,j	1.7±0.8	2.3±1.2	2.3 ± 1.0	0.0001
T1/2, h	6.3±3.5	9.1±5.3f	3.0	4.3 ± 1.6	0.0268
AUC0-∞, µg h/L	28.0±9.1c,k	63.0±31.0a	11.1±5.5a	50.6 ± 17.6a	0.0014
CL/F L/h	1.9 ± 0.5d,l	0.9 ± 0.3	1.3	1.1 ± 0.4	<0.0001
CLformation, L/h	0.6±0.2	0.5 ± 0.3	NR	0.4 ± 0.2	0.1065

^adose adjusted to 50 mg

^bOverall p value via ANOVA

Results of Tukey’s post-hoc analysis:

^cglomerulonephritis vs. CKD; p<0.01

^dglomerulonephritis vs. healthy controls; p<0.001

^eCKD vs ESRD; p<0.001

^fCKD vs healthy controls; p<0.05

^gESRD vs healthy controls; p<0.001

^hglomerulonephritis vs CKD; p<0.001

ⁱglomerulonephritis vs ESRD; p<0.01

^jglomerulonephritis vs healthy controls; p<0.01

^kglomerulonephritis vs healthy controls; p<0.05

^lglomerulonephritis vs CKD; p<0.001

Data presented as means or mean±standard deviation

CKD – chronic kidney disease

CL_formation – calculated as amount 4-hydroxyflurbiprofen in urine/flurbiprofen plasma AUC

CLr – renal clearance (of flurbiprofen)

ESRD – end stage renal disease